TELA BIO INC (TELA) Stock Fundamental Analysis
USA - NASDAQ:TELA - US8723811084 - Common Stock
1.2 USD
-0.09 (-6.98%)
1.24 USD
+0.04 (+3.33%)
Overall TELA gets a fundamental rating of 3 out of 10. We evaluated TELA against 189 industry peers in the Health Care Equipment & Supplies industry. TELA may be in some trouble as it scores bad on both profitability and health. TELA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TELA had negative earnings in the past year.
TELA had a negative operating cash flow in the past year.
In the past 5 years TELA always reported negative net income.
In the past 5 years TELA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -60.36%, TELA is not doing good in the industry: 68.78% of the companies in the same industry are doing better.
TELA has a worse Return On Equity (-443.89%) than 83.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.36% | ||
| ROE | -443.89% | ||
| ROIC | N/A |
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 67.30%, TELA is in the better half of the industry, outperforming 73.02% of the companies in the same industry.
TELA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TELA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
2. Health
2.1 Basic Checks
TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TELA has been increased compared to 1 year ago.
TELA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TELA has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.32, we must say that TELA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.32, TELA is doing worse than 72.49% of the companies in the same industry.
TELA has a Debt/Equity ratio of 4.14. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 4.14, TELA is not doing good in the industry: 86.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.32 |
ROIC/WACCN/A
WACC8.34%
2.3 Liquidity
A Current Ratio of 3.19 indicates that TELA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.19, TELA is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
A Quick Ratio of 2.59 indicates that TELA has no problem at all paying its short term obligations.
TELA has a Quick ratio of 2.59. This is in the better half of the industry: TELA outperforms 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.19 | ||
| Quick Ratio | 2.59 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.88% over the past year.
Looking at the last year, TELA shows a quite strong growth in Revenue. The Revenue has grown by 16.34% in the last year.
TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.01% yearly.
EPS 1Y (TTM)34.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.86%
Revenue 1Y (TTM)16.34%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%25.52%
3.2 Future
The Earnings Per Share is expected to grow by 15.02% on average over the next years. This is quite good.
Based on estimates for the next years, TELA will show a very strong growth in Revenue. The Revenue will grow by 21.00% on average per year.
EPS Next Y39.17%
EPS Next 2Y27.3%
EPS Next 3Y23.96%
EPS Next 5Y15.02%
Revenue Next Year14.32%
Revenue Next 2Y18.11%
Revenue Next 3Y18.86%
Revenue Next 5Y21%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TELA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TELA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TELA's earnings are expected to grow with 23.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.3%
EPS Next 3Y23.96%
5. Dividend
5.1 Amount
TELA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.2
-0.09 (-6.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners73.05%
Inst Owner Change0.09%
Ins Owners8.98%
Ins Owner Change3.03%
Market Cap47.54M
Revenue(TTM)75.32M
Net Income(TTM)-40767000
Analysts81.82
Price Target5.51 (359.17%)
Short Float %1.18%
Short Ratio4.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.65%
Min EPS beat(2)-25.31%
Max EPS beat(2)-21.99%
EPS beat(4)0
Avg EPS beat(4)-12.58%
Min EPS beat(4)-25.31%
Max EPS beat(4)-1.21%
EPS beat(8)2
Avg EPS beat(8)-1.3%
EPS beat(12)4
Avg EPS beat(12)0.07%
EPS beat(16)4
Avg EPS beat(16)-4.28%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-4.25%
Max Revenue beat(2)4.59%
Revenue beat(4)1
Avg Revenue beat(4)-6.6%
Min Revenue beat(4)-25.31%
Max Revenue beat(4)4.59%
Revenue beat(8)2
Avg Revenue beat(8)-6.05%
Revenue beat(12)3
Avg Revenue beat(12)-5.46%
Revenue beat(16)6
Avg Revenue beat(16)-3.81%
PT rev (1m)0%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.18 | ||
| P/tB | 6.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.9
BVpS0.23
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.36% | ||
| ROE | -443.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.3% | ||
| FCFM | N/A |
ROA(3y)-56.26%
ROA(5y)-51.06%
ROE(3y)-229.9%
ROE(5y)-182.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.66%
GM growth 5Y2.26%
F-Score4
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 49.91% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.19 | ||
| Quick Ratio | 2.59 | ||
| Altman-Z | -7.32 |
F-Score4
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)110.61%
Cap/Depr(5y)96.68%
Cap/Sales(3y)2.33%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.86%
EPS Next Y39.17%
EPS Next 2Y27.3%
EPS Next 3Y23.96%
EPS Next 5Y15.02%
Revenue 1Y (TTM)16.34%
Revenue growth 3Y32.99%
Revenue growth 5Y35.01%
Sales Q2Q%25.52%
Revenue Next Year14.32%
Revenue Next 2Y18.11%
Revenue Next 3Y18.86%
Revenue Next 5Y21%
EBIT growth 1Y19.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.3%
EBIT Next 3Y25.64%
EBIT Next 5Y29.7%
FCF growth 1Y19.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.67%
OCF growth 3YN/A
OCF growth 5YN/A
TELA BIO INC / TELA FAQ
Can you provide the ChartMill fundamental rating for TELA BIO INC?
ChartMill assigns a fundamental rating of 3 / 10 to TELA.
What is the valuation status for TELA stock?
ChartMill assigns a valuation rating of 1 / 10 to TELA BIO INC (TELA). This can be considered as Overvalued.
Can you provide the profitability details for TELA BIO INC?
TELA BIO INC (TELA) has a profitability rating of 1 / 10.
How financially healthy is TELA BIO INC?
The financial health rating of TELA BIO INC (TELA) is 3 / 10.
Can you provide the expected EPS growth for TELA stock?
The Earnings per Share (EPS) of TELA BIO INC (TELA) is expected to grow by 39.17% in the next year.